Revelation Biosciences, Inc. (REVB)
| Market Cap | 3.89M +170.0% |
| Revenue (ttm) | n/a |
| Net Income | -21.50M |
| EPS | -15.33 |
| Shares Out | 3.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,056 |
| Open | 1.0300 |
| Previous Close | 1.0100 |
| Day's Range | 0.9950 - 1.0300 |
| 52-Week Range | 0.8750 - 12.8800 |
| Beta | -0.10 |
| Analysts | Strong Buy |
| Price Target | 19.25 (+1,832.15%) |
| Earnings Date | May 7, 2026 |
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for REVB stock is "Strong Buy" and the 12-month stock price target is $19.25.
News
Revelation Biosciences Earnings release
Revelation Biosciences released its earnings on June 12, 2026, summarizing the period's financial results.
Revelation Biosciences Earnings release
Revelation Biosciences released its earnings on June 12, 2026, summarizing the period's financial results.
Revelation Biosciences adds two new members to AKI Advisory Board
Revelation Biosciences (REVB) announced the expansion of its Acute Kidney Injury, AKI, Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of…
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to t...
Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year
As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents…
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to t...
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to tr...
Revelation Biosciences announces formation of AKI advisory board
Revelation Biosciences (REVB) announced formation of an Acute Kidney Injury, AKI, Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This panel brings together internationally recognized Ne...
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...
Revelation Gemini data show ‘broad effect,’ says Roth Capital
Roth Capital analyst Jonathan Aschoff says Revelation Biosciences (REVB) showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokin...
Revelation Biosciences presents additional data from Prime Clinical Study
Revelation Biosciences (REVB) presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology in San Diego. Presented data demo...
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Ne...
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammatio...
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammatio...
Revelation Biosciences price target lowered to $16 from $20 at Roth Capital
Roth Capital lowered the firm’s price target on Revelation Biosciences (REVB) to $16 from $20 but keeps a Buy rating on the shares. The company ended 2025 with pro forma…
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamma...
Revelation Biosciences files to sell 4.27M shares of common stock for holders
The company is not selling any shares of common stock and will not receive any proceeds from the sale of the shares of common stock.
Revelation Biosciences Inc trading halted, news pending
19:50 EST Revelation Biosciences (REVB) Inc trading halted, news pending
Revelation Biosciences announces 1-for-4 reverse stock split
Revelation Biosciences (REVB) announced that, on January 28, the company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of the…
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will imp...
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammat...
Revelation reaches agreement with FDA on Gemini approval pathway
Revelation Biosciences (REVB) has reached agreement with the FDA on an approval pathway for Gemini as a treatment for Acute Kidney Injury. The two key agreements were a clinically relevant…
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C...
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (th...
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing i...